Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opening Session Panel Discussion

Advertisement

Advertisement




Jun
05
Today In Oncology
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
GLP-1 RAs Associated With Lower Breast Cancer Incidence
American Cancer Society Updates Colorectal Cancer Screening Guideline
Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo